Therefore, an adjuvant drug able to specifically block the MC2R would obviate the need for supraphysiological dose of glucocorticoids in CAH and prevent the undesirable effects inherent to glucocorticoid overtreatment. The gene discussed is MC2R; the disease is congenital adrenal hyperplasia.